Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

VICTOR T G LIN

Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology

NPI
1568806818
CMS profile
1388265
Location
BATON ROUGE, LA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2025 · Entire year

$3,084.71

141 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2025 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $3,004.71 140
Education $80.00 1

By paying entity

PY2025 · entire year · sorted by reported total

Paying entityAmountRecords
AstraZeneca Pharmaceuticals LP $301.84 17
Siemens Medical Solutions USA, Inc. $196.87 1
Daiichi Sankyo Inc. $170.94 7
Janssen Biotech, Inc. $146.92 8
Celgene Corporation $145.79 8
ABBVIE INC. $117.19 6
Adaptive Biotechnologies Corporation $112.21 5
GlaxoSmithKline, LLC. $111.98 6
Lilly USA, LLC $102.94 2
Caris MPI, Inc. $94.67 2
Novartis Pharmaceuticals Corporation $89.32 4
PharmaEssentia USA Corporation $89.31 4
Genentech USA, Inc. $88.00 5
E.R. Squibb & Sons, L.L.C. $86.71 5
ARRAY BIOPHARMA INC $82.21 5
SANOFI-AVENTIS U.S. LLC $80.00 1
Aveo Pharmaceuticals, Inc. $79.05 4
GENZYME CORPORATION $77.07 4
BeOne Medicines USA, Inc. $70.54 4
Incyte Corporation $68.62 3
Merck Sharp & Dohme LLC $65.68 3
PFIZER INC. $59.35 3
Bayer Healthcare Pharmaceuticals Inc. $54.60 3
Regeneron Healthcare Solutions, Inc. $43.57 2
Exelixis Inc. $38.93 2
Spectrum Pharmaceuticals Inc. $37.45 2
Gilead Sciences, Inc. $36.24 2
SpringWorks Therapeutics, Inc. $35.35 2
SOBI, INC $35.29 2
Cumberland Pharmaceuticals, Inc. $33.83 2
Geron Corporation $25.94 1
Fennec Pharmaceuticals, Inc. $24.59 1
JAZZ PHARMACEUTICALS INC. $23.12 1
Eisai Inc. $22.78 1
Takeda Pharmaceuticals U.S.A., Inc. $21.46 1
Ipsen Biopharmaceuticals, Inc $20.85 1
KYOWA KIRIN, INC. $19.82 1
Alnylam Pharmaceuticals Inc. $18.90 1
Alexion Pharmaceuticals, Inc. $18.54 1
Dendreon Pharmaceuticals LLC $18.38 1
BeiGene USA, Inc. $18.18 1
SERVIER PHARMACEUTICALS LLC $18.07 1
Tempus AI, Inc $17.95 1
Syndax Pharmaceuticals, Inc. $17.36 1
Karyopharm Therapeutics Inc. $16.00 1
Agios Pharmaceuticals, Inc. $15.60 1
Rigel Pharmaceuticals, Inc. $14.70 1

Page 3 of 3; records 101–141 of 141 matching records. This page contains 41 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

VICTOR T G LIN

NPI 1568806818 · CMS profile ID 1388265

Allopathic & Osteopathic Physicians / Internal Medicine / Hematology & Oncology

BATON ROUGE, LA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 3 of 3; records 101–141 of 141 matching records. This page contains 41 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1568806818?year=2025&recipient=provider&page=3#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
VICTOR T G LIN, NPI 1568806818, CMS profile ID 1388265. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–141 of 141 matching records. This page contains 41 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1568806818?year=2025&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
APA 7
IndustryPayments. (2026). VICTOR T G LIN, NPI 1568806818, CMS profile ID 1388265. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–141 of 141 matching records. This page contains 41 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1568806818?year=2025&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
Bluebook
VICTOR T G LIN, NPI 1568806818, CMS profile ID 1388265, IndustryPayments, General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 3; records 101–141 of 141 matching records. This page contains 41 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e. https://industrypayments.org/provider/npi-1568806818?year=2025&recipient=provider&page=3#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2025 · Physicians and non-physician practitioners · CMS publication 2026-06-30

141 matching records · $3,084.71 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 141 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 101–141 of 141.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Fennec Pharmaceuticals, Inc. $24.5904/04/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1250854870 CMS
Takeda Pharmaceuticals U.S.A., Inc. $21.4604/03/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1223869688 CMS
AstraZeneca Pharmaceuticals LP $24.3904/02/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1206633583 CMS
Daiichi Sankyo Inc. $27.5004/01/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1197060749 CMS
Novartis Pharmaceuticals Corporation $24.0904/01/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1200740863 CMS
Merck Sharp & Dohme LLC $27.5603/31/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1238144824 CMS
ARRAY BIOPHARMA INC $18.7803/28/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1231391641 CMS
Ipsen Biopharmaceuticals, Inc $20.8503/25/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1208845631 CMS
Alexion Pharmaceuticals, Inc. $18.5403/20/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1202957838 CMS
Karyopharm Therapeutics Inc. $16.0003/20/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1246652932 CMS
Novartis Pharmaceuticals Corporation $25.5303/19/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1200740861 CMS
Aveo Pharmaceuticals, Inc. $21.1503/17/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1199902488 CMS
Alnylam Pharmaceuticals Inc. $18.9003/13/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1212798187 CMS
Janssen Biotech, Inc. $14.8803/11/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1174569015 CMS
Daiichi Sankyo Inc. $27.5003/06/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1197098121 CMS
Rigel Pharmaceuticals, Inc. $14.7003/06/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1247370708 CMS
Cumberland Pharmaceuticals, Inc. $13.6503/04/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1242140038 CMS
Adaptive Biotechnologies Corporation $23.4303/03/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1254940782 CMS
Janssen Biotech, Inc. $24.0102/28/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1174571710 CMS
ABBVIE INC. $18.5402/27/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1202308263 CMS
Genentech USA, Inc. $18.5502/27/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1211604583 CMS
Celgene Corporation $20.9202/25/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1184673901 CMS
Celgene Corporation $17.7302/20/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1184673905 CMS
Tempus AI, Inc $17.9502/20/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1250348262 CMS
AstraZeneca Pharmaceuticals LP $15.9202/19/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1206170463 CMS
BeiGene USA, Inc. $18.1802/18/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1202878664 CMS
GENZYME CORPORATION $20.6802/17/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1233209178 CMS
Bayer Healthcare Pharmaceuticals Inc. $21.7102/10/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1225626760 CMS
Exelixis Inc. $21.3102/05/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1218807145 CMS
AstraZeneca Pharmaceuticals LP $19.7901/31/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1206259488 CMS
Spectrum Pharmaceuticals Inc. $19.3301/30/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1221050500 CMS
ABBVIE INC. $23.5501/28/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1202308261 CMS
Novartis Pharmaceuticals Corporation $20.7101/27/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1200740859 CMS
SpringWorks Therapeutics, Inc. $17.0301/24/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1232164501 CMS
Merck Sharp & Dohme LLC $19.0301/17/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1238059517 CMS
Janssen Biotech, Inc. $13.8801/16/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1174562231 CMS
PFIZER INC. $18.9801/07/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1230065176 CMS
PharmaEssentia USA Corporation $25.3301/07/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1246826452 CMS
Incyte Corporation $26.7001/06/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1225991111 CMS
Janssen Biotech, Inc. $17.9101/06/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1174572397 CMS
Daiichi Sankyo Inc. $28.7601/02/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1197077299 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $825.94 4
PY2020 $900.00 1
PY2022 $164.56 2
PY2023 $2,741.41 53
PY2024 $2,577.88 99
PY2025 $3,084.71 141

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2022, 2023, 2024, 2025
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019 , PY2020 , PY2022 , PY2023 , PY2024 , PY2025
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $6,101.34 2
PY2025 Principal investigator $795,142.05 63
PY2024 Principal investigator $804,779.45 52
PY2023 Principal investigator $644,023.40 44
PY2022 Principal investigator $42,912.20 7
PY2021 Principal investigator $6,530.00 1

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

65 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Eli Lilly and Company $56,045.00 12/31/2025 Non-covered Recipient Entity
THE ON EONCOLOGY RESEARCH NETWORK LLC
AN OPEN-LABEL, MULTICENTER STUDY OF LOXO-435 (LY3866288) IN ADVANCED SOLID TUMOR MALIGNANCIES WITH FGFR3 ALTERATIONS No dispute reported 06/30/2026 1187893570
Principal investigator 1 Merck Sharp & Dohme LLC $15,450.74 12/31/2025 Non-covered Recipient Entity
Mary Bird Perkins Cancer Center Baton Rouge
A Phase 2, randomized, open-label three-arm clinical study to evaluate the safety and efficacy of lenvatinib E7080,MK-7902 in combination with pembrolizumab MK-3475 versus standard of care chemotherapy and lenvatinib monotherapy in participants with r No dispute reported 06/30/2026 1232917483
Principal investigator 1 Genentech, Inc. $42,812.25 12/15/2025 Non-covered Recipient Entity
ONEONCOLOGY RESEARCH NETWORK LLC ONEONCOLOGY PARENT HLDG LLC
INTRINSIC mCRC with specific genomic alterations No dispute reported 06/30/2026 1211635190
Principal investigator 1 Aveo Pharmaceuticals, Inc. $279.06 11/10/2025 Non-covered Recipient Entity
Mary Bird Perkins Cancer Center
Head And Neck Cancer Squamous Cell Carcinoma No dispute reported 06/30/2026 1199910925
Principal investigator 1 Genentech, Inc. $195.00 11/10/2025 Non-covered Recipient Entity
ONEONCOLOGY RESEARCH NETWORK LLC ONEONCOLOGY PARENT HLDG LLC
INTRINSIC mCRC with specific genomic alterations No dispute reported 06/30/2026 1211635185
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,000.00 11/07/2025 Non-covered Recipient Entity
ONEONCOLOGY RESEARCH NETWORK LLC
A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184257859
Principal investigator 1 GlaxoSmithKline, LLC. $2,000.00 10/23/2025 Non-covered Recipient Entity
ONEONCOLOGY
A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY OF PERIOPERATIVE DOSTARLIMAB M No dispute reported 06/30/2026 1192097714
Principal investigator 1 Genentech, Inc. $13,115.00 10/17/2025 Non-covered Recipient Entity
ONEONCOLOGY RESEARCH NETWORK LLC ONEONCOLOGY PARENT HLDG LLC
INTRINSIC mCRC with specific genomic alterations No dispute reported 06/30/2026 1211635180
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $88.99 09/30/2025 Non-covered Recipient Entity
Mary Bird Perkins Cancer Center
A Randomized, Double-Blind, Phase 3 Trial of Adagrasib plus Pembrolizumab plus Chemotherapy vs. Placebo plus Pembrolizumab plus Chemotherapy in Participants with Previously Untreated, Locally Advanced or Metastatic Non-squamous Non-small Cell Lung Cancer with KRAS G12C Mutation (KRYSTAL-4) No dispute reported 06/30/2026 1235996103
Principal investigator 1 GlaxoSmithKline, LLC. $2,000.00 09/17/2025 Non-covered Recipient Entity
ONEONCOLOGY
A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY OF PERIOPERATIVE DOSTARLIMAB M No dispute reported 06/30/2026 1192097743
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,000.00 09/12/2025 Non-covered Recipient Entity
ONEONCOLOGY RESEARCH NETWORK LLC
A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184236686
Principal investigator 1 Celgene Corporation $67,206.35 09/03/2025 Non-covered Recipient Entity
Oneoncology
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Comparing the Efficacy and Safety of Golcadomide Plus R-CHOP Chemotherapy vs Placebo Plus R-CHOP Chemotherapy in Participants with Previously Untreated High-risk Large B-cell Lymphoma (GOLSEEK-1) No dispute reported 06/30/2026 1222306999
Principal investigator 1 GlaxoSmithKline, LLC. $2,000.00 08/28/2025 Non-covered Recipient Entity
ONEONCOLOGY
A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY OF PERIOPERATIVE DOSTARLIMAB M No dispute reported 06/30/2026 1192189540
Principal investigator 1 GlaxoSmithKline, LLC. $2,000.00 08/26/2025 Non-covered Recipient Entity
ONEONCOLOGY
A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY OF PERIOPERATIVE DOSTARLIMAB M No dispute reported 06/30/2026 1192189544
Principal investigator 1 AstraZeneca Pharmaceuticals LP $22,090.28 08/22/2025 Non-covered Recipient Entity
THE ONEONCOLOGY RESEARCH NETWORK LLC
A Master Protocol of an Open-Label Multi-Drug Multi-Centre Phase II Study to Evaluate the Efficacy Safety Tolerability Pharmacokinetics and Immunogenicity of Novel Combinations in Participants with Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma No dispute reported 06/30/2026 1185537449
Principal investigator 1 Novartis Pharmaceuticals Corporation $13,104.63 08/22/2025 Non-covered Recipient Entity
MARY BIRD PERKINS CANCER CENTER
An International Prospective Open-label, Multi-center, Randomized Phase III Study comparing [177Lu] Lu-PSMA-617 versus Observation to delay castration or disease recurrence in adult male patients with PSMA positive Oligometastatic Prostate Cancer (OMPC) No dispute reported 06/30/2026 1190311713
Principal investigator 1 Merck Sharp & Dohme LLC $1,740.00 08/18/2025 Non-covered Recipient Entity
Mary Bird Perkins Cancer Center Baton Rouge
A Phase 2, randomized, open-label three-arm clinical study to evaluate the safety and efficacy of lenvatinib E7080,MK-7902 in combination with pembrolizumab MK-3475 versus standard of care chemotherapy and lenvatinib monotherapy in participants with r No dispute reported 06/30/2026 1232917481
Principal investigator 1 Aveo Pharmaceuticals, Inc. $6,503.76 08/04/2025 Non-covered Recipient Entity
Mary Bird Perkins Cancer Center
A Multicenter, Randomized, Double Blind, Placebo - Controlled, Phase 3 Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV -Negative Head and Neck Squamous Cell Carcinoma. (FIERCE-HN) No dispute reported 06/30/2026 1199910917
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $85.00 07/28/2025 Non-covered Recipient Entity
MARY BIRD PERKINS CANCER CENTER
A RANDOMIZED, DOUBLE-BLIND PHASE 2/3 STUDY OF FIANLIMAB (ANTI-LAG-3 ANTIBODY) IN COMBINATION WITH CEMIPLIMAB (ANTI-PD-1 ANTIBODY) VERSUS CEMIPLIMAB MONOTHERAPY IN FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) WITH TUMORS EXPRESSING PD-L1 =50% No dispute reported 06/30/2026 1184220592
Principal investigator 1 Eli Lilly and Company $9,877.00 07/15/2025 Non-covered Recipient Entity
THE ON EONCOLOGY RESEARCH NETWORK LLC
A PHASE 3, MULTICENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY ASSESSING THE EFFICACY AND SAFETY OF OLOMORASIB IN COMBINATION WITH STANDARD OF CARE IMMUNOTHERAPY IN PARTICIPANTS WITH RESECTED OR UNRESECTABLE KRAS G12C-MUTANT, NON-SMALL CELL LUNG CANCER - SUNRAY-02 No dispute reported 06/30/2026 1187892172
Principal investigator 1 Aveo Pharmaceuticals, Inc. $7,271.98 07/07/2025 Non-covered Recipient Entity
Mary Bird Perkins Cancer Center
A Multicenter, Randomized, Double Blind, Placebo - Controlled, Phase 3 Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV -Negative Head and Neck Squamous Cell Carcinoma. (FIERCE-HN) No dispute reported 06/30/2026 1199910915
Principal investigator 1 GlaxoSmithKline, LLC. $2,000.00 06/30/2025 Non-covered Recipient Entity
ONEONCOLOGY
A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY OF PERIOPERATIVE DOSTARLIMAB M No dispute reported 06/30/2026 1192097728
Principal investigator 1 GlaxoSmithKline, LLC. $1,750.00 06/27/2025 Non-covered Recipient Entity
ONEONCOLOGY
A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY OF PERIOPERATIVE DOSTARLIMAB M No dispute reported 06/30/2026 1192097735
Principal investigator 1 Aveo Pharmaceuticals, Inc. $279.06 06/18/2025 Non-covered Recipient Entity
Mary Bird Perkins Cancer Center
A Multicenter, Randomized, Double Blind, Placebo - Controlled, Phase 3 Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV -Negative Head and Neck Squamous Cell Carcinoma. (FIERCE-HN) No dispute reported 06/30/2026 1199910923
Principal investigator 1 Eli Lilly and Company $5,999.00 06/17/2025 Non-covered Recipient Entity
THE ON EONCOLOGY RESEARCH NETWORK LLC
SUNRAY-01 A GLOBAL PIVOTAL STUDY IN PARTICIPANTS WITH KRAS G12C-MUTANT LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER COMPARING FIRST LINE TREATMENT OF LY3537982 AND PEMBROLIZUMAB VS PLACEBO AND PEMBROLIZUMAB IN THOSE WITH PD L1 EXPRESSION 50% OR LY3537982 AND PEMBROLIZUMAB PEMETREXED PLATINUM VS PLACEBO AND PEMBROLIZUMAB PEMETREXED PLATINUM REGARDLESS OF PD-L1 EXPRESSION No dispute reported 06/30/2026 1187891220
Principal investigator 1 Novartis Pharmaceuticals Corporation $10,000.00 06/03/2025 Non-covered Recipient Entity
MARY BIRD PERKINS CANCER CENTER
An International Prospective Open-label, Multi-center, Randomized Phase III Study comparing [177Lu] Lu-PSMA-617 versus Observation to delay castration or disease recurrence in adult male patients with PSMA positive Oligometastatic Prostate Cancer (OMPC) No dispute reported 06/30/2026 1190305361
Principal investigator 1 Genentech, Inc. $21,108.00 05/28/2025 Non-covered Recipient Entity
ONEONCOLOGY RESEARCH NETWORK LLC ONEONCOLOGY PARENT HLDG LLC
INTRINSIC mCRC with specific genomic alterations No dispute reported 06/30/2026 1211635166
Principal investigator 1 GlaxoSmithKline, LLC. $2,000.00 05/13/2025 Non-covered Recipient Entity
ONEONCOLOGY
A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY OF PERIOPERATIVE DOSTARLIMAB M No dispute reported 06/30/2026 1192097767
Principal investigator 1 GlaxoSmithKline, LLC. $2,000.00 05/13/2025 Non-covered Recipient Entity
ONEONCOLOGY
A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY OF PERIOPERATIVE DOSTARLIMAB M No dispute reported 06/30/2026 1192150623
Principal investigator 1 Aveo Pharmaceuticals, Inc. $906.75 05/12/2025 Non-covered Recipient Entity
Mary Bird Perkins Cancer Center
A Multicenter, Randomized, Double Blind, Placebo - Controlled, Phase 3 Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV -Negative Head and Neck Squamous Cell Carcinoma. (FIERCE-HN) No dispute reported 06/30/2026 1199910921
Principal investigator 1 Janssen Research & Development, LLC $250.00 05/12/2025 Non-covered Recipient Entity
THE ONEONCOLOGY RESEARCH NETWORK LL C
A Randomized, Open-label Phase 3 Study of Amivantamab + FOLFIRI Versus Cetuximab/Bevacizumab + FOLFIRI in Participants With KRAS/NRAS and BRAF Wildtype Recurrent Metastatic Colorectal Cancer Who Have Received Prior Chemotherapy No dispute reported 06/30/2026 1175421238
Recipient F. Hoffmann-La Roche AG $3,050.67 05/08/2025 Covered Recipient Physician A rising tide lifts all boats in the personalized cancer care continuum for mNSCLC: bridging inequities in NGS fosters equity in targeted treatment No dispute reported 06/30/2026 1211539469
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $14,000.00 05/02/2025 Non-covered Recipient Entity
ONEONCOLOGY RESEARCH NETWORK LLC
A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184191969
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,000.00 05/02/2025 Non-covered Recipient Entity
ONEONCOLOGY RESEARCH NETWORK LLC
A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184191971
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,500.00 05/02/2025 Non-covered Recipient Entity
ONEONCOLOGY RESEARCH NETWORK LLC
A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184191973
Principal investigator 1 AstraZeneca Pharmaceuticals LP $114,607.31 04/30/2025 Non-covered Recipient Entity
THE ONEONCOLOGY RESEARCH NETWORK LLC
A Phase III, Open-label, Randomised Study of Datopotamab Deruxtecan (Dato-DXd) With or Without Durvalumab Compared with Investigators Choice of Chemotherapy (Paclitaxel, Nab-paclitaxel or Gemcitabine + Carboplatin) in Combination With Pembrolizumab in Patients with PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05) No dispute reported 06/30/2026 1185537453
Principal investigator 1 Janssen Research & Development, LLC $6,541.00 04/28/2025 Non-covered Recipient Entity
THE ONEONCOLOGY RESEARCH NETWORK LL C
A Randomized, Open-label Phase 3 Study of Amivantamab + FOLFIRI Versus Cetuximab/Bevacizumab + FOLFIRI in Participants With KRAS/NRAS and BRAF Wildtype Recurrent Metastatic Colorectal Cancer Who Have Received Prior Chemotherapy No dispute reported 06/30/2026 1175421182
Principal investigator 1 Janssen Research & Development, LLC $20,500.00 04/28/2025 Non-covered Recipient Entity
THE ONEONCOLOGY RESEARCH NETWORK LL C
A Randomized, Open-label Phase 3 Study of Amivantamab + FOLFIRI Versus Cetuximab/Bevacizumab + FOLFIRI in Participants With KRAS/NRAS and BRAF Wildtype Recurrent Metastatic Colorectal Cancer Who Have Received Prior Chemotherapy No dispute reported 06/30/2026 1175421189
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,227.90 04/28/2025 Non-covered Recipient Entity
MARY BIRD PERKINS CANCER CENTER
A RANDOMIZED, DOUBLE-BLIND PHASE 2/3 STUDY OF FIANLIMAB (ANTI-LAG-3 ANTIBODY) IN COMBINATION WITH CEMIPLIMAB (ANTI-PD-1 ANTIBODY) VERSUS CEMIPLIMAB MONOTHERAPY IN FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) WITH TUMORS EXPRESSING PD-L1 =50% No dispute reported 06/30/2026 1184190357
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,463.35 04/28/2025 Non-covered Recipient Entity
MARY BIRD PERKINS CANCER CENTER
A RANDOMIZED, DOUBLE-BLIND PHASE 2/3 STUDY OF FIANLIMAB (ANTI-LAG-3 ANTIBODY) IN COMBINATION WITH CEMIPLIMAB (ANTI-PD-1 ANTIBODY) VERSUS CEMIPLIMAB MONOTHERAPY IN FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) WITH TUMORS EXPRESSING PD-L1 =50% No dispute reported 06/30/2026 1184190359
Principal investigator 1 Eli Lilly and Company $866.01 04/23/2025 Non-covered Recipient Entity
MARY BIRD PERKINS CANCER CENTER
A PHASE 3, MULTICENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY ASSESSING THE EFFICACY AND SAFETY OF OLOMORASIB IN COMBINATION WITH STANDARD OF CARE IMMUNOTHERAPY IN PARTICIPANTS WITH RESECTED OR UNRESECTABLE KRAS G12C-MUTANT, NON-SMALL CELL LUNG CANCER - SUNRAY-02 No dispute reported 06/30/2026 1187886160
Principal investigator 1 Aveo Pharmaceuticals, Inc. $5,907.33 04/11/2025 Non-covered Recipient Entity
Mary Bird Perkins Cancer Center
A Multicenter, Randomized, Double Blind, Placebo - Controlled, Phase 3 Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV -Negative Head and Neck Squamous Cell Carcinoma. (FIERCE-HN) No dispute reported 06/30/2026 1199910919
Principal investigator 1 Eli Lilly and Company $95,861.60 04/03/2025 Non-covered Recipient Entity
MARY BIRD PERKINS CANCER CENTER
A PHASE 1A/1B STUDY OF LY3537982 IN PATIENTS WITH KRAS G12C-MUTANT ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1187886792
Recipient F. Hoffmann-La Roche AG $3,050.67 03/31/2025 Covered Recipient Physician A rising tide lifts all boats in the personalized cancer care continuum for mNSCLC: bridging inequities in NGS fosters equity in targeted treatment No dispute reported 06/30/2026 1211539473
Principal investigator 1 GlaxoSmithKline, LLC. $2,000.00 03/21/2025 Non-covered Recipient Entity
ONEONCOLOGY
A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY OF PERIOPERATIVE DOSTARLIMAB M No dispute reported 06/30/2026 1192097721
Principal investigator 1 GlaxoSmithKline, LLC. $2,000.00 03/21/2025 Non-covered Recipient Entity
ONEONCOLOGY
A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY OF PERIOPERATIVE DOSTARLIMAB M No dispute reported 06/30/2026 1192150627
Principal investigator 1 Aveo Pharmaceuticals, Inc. $8,128.29 03/18/2025 Non-covered Recipient Entity
Mary Bird Perkins Cancer Center
A Multicenter, Randomized, Double Blind, Placebo - Controlled, Phase 3 Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV -Negative Head and Neck Squamous Cell Carcinoma. (FIERCE-HN) No dispute reported 06/30/2026 1199910913
Principal investigator 1 BeiGene USA, Inc. $1,573.00 03/04/2025 Non-covered Recipient Entity
Mary Bird Perkins Cancer Center
A Phase 1/2, Open-Label, Dose-Escalation and -Expansion Study of the Bruton Tyrosine Kinase Targeted Protein Degrader BGB-16673 in Patients With B-Cell Malignancies No dispute reported 06/30/2026 1190320236
Principal investigator 1 BeiGene USA, Inc. $1,413.00 02/25/2025 Non-covered Recipient Entity
Mary Bird Perkins Cancer Center
A Phase 1/2, Open-Label, Dose-Escalation and -Expansion Study of the Bruton Tyrosine Kinase Targeted Protein Degrader BGB-16673 in Patients With B-Cell Malignancies No dispute reported 06/30/2026 1190320234
Principal investigator 1 GlaxoSmithKline, LLC. $2,000.00 02/24/2025 Non-covered Recipient Entity
ONEONCOLOGY
A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY OF PERIOPERATIVE DOSTARLIMAB M No dispute reported 06/30/2026 1192150618
Principal investigator 1 AstraZeneca Pharmaceuticals LP $22,750.00 02/12/2025 Non-covered Recipient Entity
THE ONEONCOLOGY RESEARCH NETWORK LLC
A Phase III, Randomized,Open Label,Multi Center,Global Study of Volrustomig as Sequential Therapy Versus Observation in Participants with Unresected Locally Advanced Head and Neck Squamous Cell Carcinoma,Who Have Not Progressed Following Definitive Concurrent Chemoradiotherapy No dispute reported 06/30/2026 1185537451
Principal investigator 1 GlaxoSmithKline, LLC. $2,000.00 02/10/2025 Non-covered Recipient Entity
ONEONCOLOGY
A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY OF PERIOPERATIVE DOSTARLIMAB M No dispute reported 06/30/2026 1192097750
Principal investigator 1 GlaxoSmithKline, LLC. $2,000.00 02/10/2025 Non-covered Recipient Entity
ONEONCOLOGY
A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY OF PERIOPERATIVE DOSTARLIMAB M No dispute reported 06/30/2026 1192097756
Principal investigator 1 GlaxoSmithKline, LLC. $1,750.00 02/07/2025 Non-covered Recipient Entity
ONEONCOLOGY
A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY OF PERIOPERATIVE DOSTARLIMAB M No dispute reported 06/30/2026 1192097762
Principal investigator 1 GlaxoSmithKline, LLC. $2,000.00 02/07/2025 Non-covered Recipient Entity
ONEONCOLOGY
A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY OF PERIOPERATIVE DOSTARLIMAB M No dispute reported 06/30/2026 1192150631
Principal investigator 1 Aveo Pharmaceuticals, Inc. $9,588.15 02/03/2025 Non-covered Recipient Entity
Mary Bird Perkins Cancer Center
A Multicenter, Randomized, Double Blind, Placebo - Controlled, Phase 3 Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV -Negative Head and Neck Squamous Cell Carcinoma. (FIERCE-HN) No dispute reported 06/30/2026 1199910905
Principal investigator 1 Aveo Pharmaceuticals, Inc. $41,077.16 02/03/2025 Non-covered Recipient Entity
Mary Bird Perkins Cancer Center
A Multicenter, Randomized, Double Blind, Placebo - Controlled, Phase 3 Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV -Negative Head and Neck Squamous Cell Carcinoma. (FIERCE-HN) No dispute reported 06/30/2026 1199910909
Principal investigator 1 Celgene Corporation $65,818.60 01/29/2025 Non-covered Recipient Entity
Oneoncology
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Comparing the Efficacy and Safety of Golcadomide Plus R-CHOP Chemotherapy vs Placebo Plus R-CHOP Chemotherapy in Participants with Previously Untreated High-risk Large B-cell Lymphoma (GOLSEEK-1) No dispute reported 06/30/2026 1222306957
Principal investigator 1 Eli Lilly and Company $2,351.73 01/27/2025 Non-covered Recipient Entity
MARY BIRD PERKINS CANCER CENTER
SUNRAY-01 A GLOBAL PIVOTAL STUDY IN PARTICIPANTS WITH KRAS G12C-MUTANT LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER COMPARING FIRST LINE TREATMENT OF LY3537982 AND PEMBROLIZUMAB VS PLACEBO AND PEMBROLIZUMAB IN THOSE WITH PD L1 EXPRESSION 50% OR LY3537982 AND PEMBROLIZUMAB PEMETREXED PLATINUM VS PLACEBO AND PEMBROLIZUMAB PEMETREXED PLATINUM REGARDLESS OF PD-L1 EXPRESSION No dispute reported 06/30/2026 1187885464
Principal investigator 1 BeiGene USA, Inc. $22,698.00 01/21/2025 Non-covered Recipient Entity
Mary Bird Perkins Cancer Center
A Phase 1/2, Open-Label, Dose-Escalation and -Expansion Study of the Bruton Tyrosine Kinase Targeted Protein Degrader BGB-16673 in Patients With B-Cell Malignancies No dispute reported 06/30/2026 1190322580
Principal investigator 1 Aveo Pharmaceuticals, Inc. $11,911.77 01/07/2025 Non-covered Recipient Entity
Mary Bird Perkins Cancer Center
A Multicenter, Randomized, Double Blind, Placebo - Controlled, Phase 3 Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV -Negative Head and Neck Squamous Cell Carcinoma. (FIERCE-HN) No dispute reported 06/30/2026 1199910907
Principal investigator 1 Aveo Pharmaceuticals, Inc. $450.00 01/07/2025 Non-covered Recipient Entity
Mary Bird Perkins Cancer Center
A Multicenter, Randomized, Double Blind, Placebo - Controlled, Phase 3 Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV -Negative Head and Neck Squamous Cell Carcinoma. (FIERCE-HN) No dispute reported 06/30/2026 1199910911
Principal investigator 1 GlaxoSmithKline, LLC. $2,000.00 01/07/2025 Non-covered Recipient Entity
ONEONCOLOGY
A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY OF PERIOPERATIVE DOSTARLIMAB M No dispute reported 06/30/2026 1192150610
Principal investigator 1 GlaxoSmithKline, LLC. $2,000.00 01/07/2025 Non-covered Recipient Entity
ONEONCOLOGY
A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY OF PERIOPERATIVE DOSTARLIMAB M No dispute reported 06/30/2026 1192150614
Principal investigator 1 GlaxoSmithKline, LLC. $2,000.00 01/07/2025 Non-covered Recipient Entity
ONEONCOLOGY
A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY OF PERIOPERATIVE DOSTARLIMAB M No dispute reported 06/30/2026 1192150635